BioPharmSignal logoBioPharmSignal

Biotech News

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Oculis (OCS)OculisClinical readout

Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with topline results expected in June 2026 A non-invasive topical treatment for diabetic macular edema (DME) has the potential to address significant unmet needs for early treatment intervention and for

Open original release

Related news

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

OCSOculis2026-05-05 08:00 EST

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

MGTXMeiraGTx2026-04-16 11:00 EST

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

MGTXMeiraGTx2026-04-14 12:30 EST

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

VRDNViridian Therapeutics2022-03-21 20:05 EST

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

TARSTarsus Pharmaceuticals2026-03-31 12:30 EST

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

CLSDClearside Biomedical2025-08-26 12:05 EST

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

VRDNViridian Therapeutics2021-12-20 12:00 EST

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

OCULOcular Therapeutix2026-04-29 11:00 EST

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

CLSDClearside Biomedical2025-11-24 12:05 EST

Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

View all latest news

Oculis

Oculis is an eye-disease company focused on ophthalmology therapies and topical or local delivery approaches. Its strategy is to build a differentiated eye-care franchise in high-value indications.

Recent company news

OCSOculis2026-05-29 19:06 EST

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

OCSOculis2026-05-14 20:05 EST

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors

OCSOculis2026-05-11 20:07 EST

Oculis Reports Q1 2026 Financial Results and Provides Company Update

OCSOculis2026-05-07 08:58 EST

Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial

OCSOculis2026-05-05 08:00 EST

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

Stock data

Close
11.02 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States